Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04033081 · ClinicalTrials.gov registry record · Phase 4
Registry of Sarcoma Patients Treated With Permanently Implantable LDR CivaSheet®
A Phase 4 study of Sarcoma, sponsored by CivaTech Oncology.
- Active
- Registry status
- Phase 4
- Development phase
- 100
- Enrollment target
- 1
- Study location
NCT04033081: Active Phase 4 study of Sarcoma, sponsored by CivaTech Oncology.
NCT04033081 is a Phase 4 study of Sarcoma that is active but no longer recruiting, run by CivaTech Oncology. The registered enrollment target is 100 participants, below the 920-participant average among 122 other Sarcoma trials with a reported enrollment target (89% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04033081, a Phase 4 study of Sarcoma, is active but no longer recruiting, sponsored by CivaTech Oncology.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 4
- Development phase
- 100 participants
- Enrollment target
- 1
- Study location
Study Summary
This patient study will determine the safety and toxicity of a permanently implantable brachytherapy source - CivaSheet® - which is designed to deliver a therapeutic dose of low dose rate (LDR) radiation with polymer encased Palladium-103. CivaSheet will be implanted in sarcoma patients with disease presenting in the retroperitoneum, abdomen, pelvis and trunk.
Primary Outcome
rate of greater than or equal to Grade 3 toxicity events based on CTCAE criteria
Conditions Studied
Interventions
- DEVICE CivaSheet
Study Locations (1)
Pennsylvania
- Fox Chase Cancer Center - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 100 participants |
| Start Date | 2020-04-30 |
| Est. Completion | 2030-04 |
| Phase | Phase 4 |
What the registry record for NCT04033081 still lists
NCT04033081 is an interventional study that assigns participants to a tested intervention. The registered 100 participants enrollment target is mid-sized for trials with a published cap, below the 920-participant average among 122 other Sarcoma trials with a reported enrollment target (89% lower).
The record links to 1 condition, with Sarcoma appearing as the primary indexed condition, and to 1 intervention - of which CivaSheet is the first listed.
NCT04033081 reports a single indexed study location in Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT04033081 about?
NCT04033081 is a clinical study titled "Registry of Sarcoma Patients Treated With Permanently Implantable LDR CivaSheet®". This patient study will determine the safety and toxicity of a permanently implantable brachytherapy source - CivaSheet® - which is designed to deliver a therapeutic dose of low dose rate (LDR) radiation with polymer encased Palladium-103. CivaSheet will be implanted in sarcoma patients with disease...
What is the current status of trial NCT04033081?
This trial is currently active not recruiting. It is a Phase 4 study. The enrollment target is 100 participants. The study started on 2020-04-30. Estimated completion is 2030-04.
What conditions does trial NCT04033081 study?
This clinical trial studies the following conditions: Sarcoma.
What interventions are being tested in trial NCT04033081?
The interventions under investigation include: CivaSheet (DEVICE).
Who is sponsoring clinical trial NCT04033081?
This trial is sponsored by CivaTech Oncology, which has 6 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04033081 being conducted?
This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Sarcoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04033081's enrollment target sits among peer trials
100 42nd of 122 higher than 80 of 122 other Sarcoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Sarcoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Hyperbaric Oxygen Therapy for Soft Tissue Sarcoma Pilot Study
RECRUITING · Phase 4
-
WATCH (Wearable Artificial inTelligence for Cardiac Function and Health Monitoring)
RECRUITING · NA
-
LCI-SAR-BSTS-CTDNA-001: Circulating Tumor DNA Liquid Biopsy in Sarcoma Patients
RECRUITING
-
Palbociclib and Pembrolizumab in Sarcoma
RECRUITING · Phase 1
-
Abductor Reattachment Methods in Proximal Femur Replacements: What is the Best Method?
RECRUITING
-
Autologous B7-H3 Chimeric Antigen Receptor T Cells in Relapsed/Refractory Solid Tumors
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01048281 · 100 participants
Clinical & Pathological Studies of Upper Gastrointestinal Carcinoma
- NCT01161199 · 100 participants
The Use of Leukapheresis to Support HIV Pathogenesis Studies
- NCT01327690 · 100 participants · Early Phase 1
Mental Health in Veterans and Families After Group Therapies
- NCT01730781 · 100 participants
Imaging Cannabinoid Receptors Using Positron Emission Tomography (PET) Scanning
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI
- NCT06358040 · started 2026-10 · NA
Opioid Dispenser for Microdiscectomy/Laminectomy